Skip to search.
 FTSE 100 Down 0.71%

KaloBios Pharmaceuticals, Inc. (KBIO)

-NasdaqGM
0.65 Down 0.04(5.80%) 6 Mar 20:59
Add to Portfolio
Prev Close:0.69
Open:0.70
Bid:0.64 x 500
Ask:0.67 x 9900
1y Target Est:5.00
Beta:4.49
Earnings Date:23 Mar - 27 Mar (Est.)
Day's Range:0.61 - 0.72
52wk Range:0.36 - 3.38
Volume:1,930,759
Avg Vol (3m):1,324,550
Market Cap:21.44m
P/E (ttm):N/A
EPS (ttm):-1.17
Div & Yield:N/A (N/A)
Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.

Headlines

  • No Headlines available for KBIO at this time.

Comparison

Symbol% ChgMkt Cap
KBIODown 5.80%21.44m
VRTXDown 0.49%30.59b

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):5,690.26
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-14) :-1.16
Quarterly EPS Est (Dec-14) :-0.30
Mean Recommendation*:2.3
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback